Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIRâ"¢ and ADAPTIR-FLEXâ"¢ platform technologies, today announced executive leadership transitions to support the Company's continued execution, drive achievement of l ...

As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 81-1567056 (I.R.S. Employer Identification Number) 2401 4th Avenue ...

Core Insights - Aptevo Therapeutics has entered into a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP, enhancing its financial flexibility and extending its funding runway into 2029 [1][2][3] Financial Flexibility - The ELOC allows Aptevo to raise funds incrementally at its discretion under market-based conditions, providing affordable capital financing with minimal fees and no warrants [2][3] - The combination of the ELOC and cash on hand is projected to fund the company for three years, allowing for the achievement of key clinical and preclinical milestones [1][3] Clinical Development - Aptevo's portfolio includes five CD3-engaging assets, with mipletamig being a first-in-class CD123 x CD3 bispecific currently evaluated in a Phase 1b/2 trial for frontline acute myeloid leukemia (AML) [5][7] - Mipletamig has shown high remission rates and a favorable safety profile in over 100 patients across three trials, with no observed cytokine release syndrome events [5][6] Pipeline and Innovation - The company is advancing a portfolio of tumor-directed CD3 programs, including bispecific candidates for prostate cancer and solid tumors, utilizing proprietary CRIS-7-derived CD3 binding domains [6][7] - Aptevo has two clinical candidates and six preclinical candidates targeting various solid tumors, all developed from its ADAPTIR and ADAPTIR-FLEX platforms [7]

Core Viewpoint - Aptevo Therapeutics Inc. will conduct a reverse stock split at a ratio of 1-for-18, effective December 29, 2025, at 5:01 p.m. [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies for its therapeutic developments [1]

Core Insights - 100% of patients in Cohorts 1-3 remain free of cytokine release syndrome, indicating a strong safety profile for the CD3 design used in the study [1] - The study evaluates mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy [1] - Preliminary results were presented at the American Society of Hematology Annual Meeting, highlighting the potential of the ADAPTIR™ and ADAPTIR-FLEX™ platform technologies developed by the company [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies in its research and development efforts [1] Industry Context - The ongoing Phase 1b/2 RAINIER study is significant for the treatment of acute myeloid leukemia, particularly for patients who cannot undergo intensive chemotherapy [1] - The combination of mipletamig with standard treatments like azacitidine and venetoclax represents a potential advancement in the therapeutic options available for AML [1]

Core Viewpoint - Aptevo Therapeutics Inc. (APVO) has shown a downtrend recently, losing 12% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price [4][5]. - The occurrence of this pattern at the bottom of a downtrend suggests that bulls have successfully halted further price declines, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for APVO, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 62.1% over the last 30 days, reflecting strong agreement among analysts regarding the company's improved earnings potential [8]. - APVO holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Insights - Aptevo Therapeutics has presented preclinical data for its trispecific antibody candidate, APVO451, at the Society for Immunotherapy of Cancer Annual Meeting, highlighting its potential in treating hard-to-treat solid tumors [1][2]. Company Update - APVO451 is designed to address the challenge of immune suppression in solid tumors, such as urothelial, breast, and pancreatic cancers, by utilizing a proprietary CRIS-7-derived CD3 binding domain [2][3]. - The molecule aims to activate the intratumoral immune system, enhancing the ability to target and kill tumor cells effectively [3]. Key Findings from the Presentation - APVO451 demonstrated local activation of T-cells and antigen-presenting cells (APCs) only when bound to the target protein, nectin-4, indicating a favorable safety profile [4]. - The candidate showed dual immune re-activation by stimulating T-cell effector functions and restoring APC function, addressing a common failure point in solid tumor treatments [4]. - In tumor models simulating suppression, APVO451 was more effective in eliminating nectin-4-positive tumor cells compared to standard CD3 T-cell engagers, suggesting its potential to overcome suppressive tumor environments [4]. Next Steps - Aptevo is advancing APVO451 through ongoing preclinical studies to support IND-enabling work and future clinical development targeting nectin-4-expressing solid tumors [5]. About APVO451 - APVO451 is a trispecific ADAPTIR-FLEX therapeutic candidate designed to engage CD3 and CD40, aiming to restore immune engagement in suppressive solid tumors while minimizing off-tumor activation [6]. About Aptevo Therapeutics - Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment, with two clinical candidates currently in trials [7].

Clinical Development - Mipletamig reported an 89% remission rate among evaluable frontline AML patients, with 100% remission in Cohort 3 of the ongoing RAINIER trial[99]. - No cytokine release syndrome (CRS) observed among evaluable frontline patients to date, distinguishing it from other treatments[99]. - The ongoing Phase 1b trial for mipletamig was initiated in August 2024, with favorable results reported to date[91]. - The company has two clinical candidates and six preclinical candidates currently in development, focusing on novel immunotherapy for cancer treatment[91]. - The company has an obligation to make a $2.0 million milestone payment upon dosing the first patient in a Phase 2 clinical trial of mipletamig under the OMT License Agreement[124]. Financial Performance - Research and development expenses increased by $0.9 million to $4.0 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024[102]. - General and administrative expenses rose by $1.5 million to $3.6 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024[104]. - Net cash provided by financing activities was $32.7 million for the nine months ended September 30, 2025, compared to $8.9 million for the same period in 2024[109]. - Total research and development expenses for the nine months ended September 30, 2025, were $11.0 million, up from $10.5 million in the same period in 2024[102]. - For the nine months ended September 30, 2025, net cash used in operating activities was $20.4 million, indicating ongoing operational losses[117]. - The company anticipates significant operating losses for the next several years as it continues to develop its product candidates, requiring substantial additional funding[117]. Capital Raising and Agreements - The company raised $18.7 million net in the third quarter, extending cash runway into Q4 2026[99]. - The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the issuance of up to $25 million in common stock over 36 months, with $15 million raised from 8.3 million shares issued as of September 30, 2025[110]. - Under the At The Market Offering Agreement (ATM Agreement), the company raised $7.6 million from the issuance of 2.8 million shares at an average price of $2.74 per share for the nine months ended September 30, 2025[111]. - The company has no remaining availability under the ATM Agreement due to limitations, but has $10 million remaining under the SEPA[111][118]. - The company has 12,535,033 common warrants outstanding, which could yield up to $23.9 million in gross proceeds if exercised[115]. - The company received $9.6 million from XOMA for the sale of future deferred payments and potential milestones related to IXINITY, with an additional $5.8 million in milestone payments contingent on regulatory achievements[114]. Market and Operational Challenges - The company may face delays in clinical trials and partnerships due to macroeconomic factors, including inflation and potential impacts on partners' financial stability[120]. - The company has cash and cash equivalents of $21.1 million and an accumulated deficit of $269.2 million as of September 30, 2025[116].

Clinical Trials and Product Development - 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy across two trials, including 100% remission in Cohort 3 of the RAINIER trial[3] - Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules[4] - Aptevo's pipeline now includes six preclinical candidates targeting various solid tumors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms[18] Financial Performance - The company raised $18.7 million in Q3 2025 and an additional $4.1 million post-quarter, extending its cash runway into Q4 2026[10] - Cash and cash equivalents totaled $21.1 million as of September 30, 2025, increasing to $25.2 million after additional fundraising[10] - Research and development expenses rose to $4.0 million in Q3 2025, up from $3.1 million in Q3 2024, primarily due to increased mipletamig and employee costs[11] - General and administrative expenses increased to $3.6 million in Q3 2025, compared to $2.1 million in Q3 2024, mainly due to higher employee costs[12] - Aptevo reported a net loss of $7.5 million or $2.23 per share for Q3 2025, compared to a net loss of $5.1 million or $357.86 per share in Q3 2024[12] - The total assets of Aptevo increased to $26.996 million as of September 30, 2025, from $15.591 million at the end of 2024[15] - The company’s accumulated deficit reached $269.2 million as of September 30, 2025, compared to $247.6 million at the end of 2024[15] Risks and Uncertainties - Aptevo's actual results may differ materially from forward-looking statements due to various risks, including clinical trial uncertainties and regulatory changes[21] - The company faces known and unknown risks that could impact the availability or commercial potential of its product candidates[21] - Macroeconomic conditions such as rising inflation, interest rates, and decreased consumer confidence are potential factors affecting Aptevo's performance[21] - The ongoing geopolitical risks, including the war between Russia and Ukraine, may also influence the company's business environment[21] - Aptevo does not assume any obligation to update forward-looking statements unless required by law[21]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]